49986 Federal Register / Vol. 62, No. 185 / Wednesday, September 24, 1997 / Notices

woman, and for a 70 Kg man, the daily

intakes associated with the above EDI,

expressed as μg/Kg/day and as percent

RfD utilization are:

Dietary Exposure

Percent

RfD Utilized

Infant 0.65 μg/Kg/

day

1.71

Child 0.47 μg/Kg/

day

1.24

Woman 0.24 μg/Kg/

day

0.632

Man 0.20 μg/Kg/

day

0.526

Yoshitomi Fine Chemicals, Ltd. notes

that at 40 CFR 180.1(l) EPA has defined

that a ‘‘negligible residue ... Ordinarily

... will add to the diet an amount which

will be less than 1/2,000th of the

amount that has been demonstrated to

have no effect from feeding studies on

the most sensitive animal species

tested.’’ This, for a 100-fold uncertainty

factor based RfD, means an RfD

utilization of 5% or less. Yoshitomi

considers, therefore, that under the

hypothetical worst case dietary

exposure assessment RYH–86 residues

are clearly negligible residues.

i. Drinking water. The use of RYH–86

as a slimicide for pulp and paper mills

does not provide for entry of RYH–86

into drinking water sources. Spent

process water from such sites is treated

as waste water, typically on-site, prior to

release into surface waters. In a Finnish

paper mill, with a use level of 1.5 ppm

in the water (as an initial load to the

slurry water) no RYH–86 was detected

in air or water at sites by the paper

making machine (detection limits were

4.5 ng/L in water and 3×10–6 mg/dm3).

Water samples which were examined

included samples from the waste water

holding pond and discharge from the

on-site waste water treatment plant.

2. Non-dietary exposure. RYH–86 is

an industrial-use slimicide whose only

other registered use (i.e., aside from

slimicide use in pulp and paper mills)

is as a slime control agent in recirculating cooling water. All of the uses

of RYH–86 involve only occupational

exposures. There are no registrations

and no intended uses in residential

scenarios. There are, therefore, no Food

Quality Protection Act covered nondietary exposures to RYH–86.

D. Cumulative Effects

There is no reliable information to

indicate that RYH–86 has a common

mechanism of toxicity with any other

chemical compound.

E. Safety Determination

1. U.S. population. Since the use of

RYH–86 as a slimicide in pulp and

paper mills is, under hypothetical worst

case conditions, anticipated to lead to

only negligible adult dietary exposures

(i.e., not greater than 0.63% of the RfD

for adults with ‘‘negligible’’ defined at

40 CFR 180.1(l) as ‘‘ordinarily’’ not

greater than 5% of the RfD) Yoshitomi

Fine Chemicals, Ltd. concludes that

there is a reasonable certainty that no

harm to the general adult population

will result from dietary exposure to

RYH–86 residues which could occur in

food contact paper and paperboard

produced in pulp and paper mills

utilizing RYH–86 for slime control in

accordance with its FIFRA labeling.

2. Infants and children. Since the use

of RYH–86 as a slimicide in pulp and

paper mills is, under hypothetical worst

case conditions, anticipated to lead to

only negligible dietary exposures (i.e.,

not greater than 1.71% of the RfD for

infants and not greater than 1.24% of

the RfD for children with ‘‘negligible’’

defined at 40 CFR 180.1(l) as

‘‘ordinarily’’ not greater than 5% of the

RfD) Yoshitomi Fine Chemicals, Ltd.

concludes that there is a reasonable

certainty that no harm to infants and

children will result from dietary

exposure to RYH–86 residues which

could occur in food contact paper and

paperboard produced in pulp and paper

mills utilizing RYH–86 for slime control

in accordance with its FIFRA labeling.

3. Sensitive individuals. The RfD for

RYH–86 is based on gastro-intestinal

irritation as the effect which occurs at

lowest dose in animal gavage studies.

Since the effect of irritation is a physicochemical effect, the existence of

metabolic differences among persons is

not reasonably expected to be a factor

producing individuals with special

sensitivity to RYH–86. Also, since: (a)

physico-chemical effects like irritancy

usually do not at all occur well below

a threshold concentration of irritant;

and, (b) the RfD is based on gavage

studies in which RYH–86 is directly

delivered to the gastric compartment

whereas daily dietary consumption of

the RfD amount leads to a lower peak

GI tract level than would occur after

gavage administration of the RfD

amount, it can be expected that even for

persons with pre-existing conditions

such as ulcers, colitis, and similar

pathologies that dietary exposures to

RYH–86 at levels up to the proposed

RfD will not exacerbate such conditions.

Therefore, Yoshitomi Fine Chemicals,

Ltd. concludes that there is a reasonable

certainty that no harm to persons with

pre-existing GI-tract problems will

result from dietary exposure to RYH–86

residues which could occur in food

contact paper and paperboard produced

in pulp and paper mills utilizing RYH–

86 for slime control in accordance with

its FIFRA labeling.

F. International Tolerances

There are no Codex maximum residue

levels (MRLs) established for residues of

RYH–86 resulting from the use of RYH–

86.

[FR Doc. 97–25338 Filed 9–23–97; 8:45 am]

BILLING CODE 6560–50–F

FEDERAL COMMUNICATIONS

COMMISSION

[Report No. 2225]

Petitions for Reconsideration and

Clarification of Action in Rulemaking

Proceedings

September 19, 1997.

Petitions for reconsideration and

clarification have been filed in the

Commission’s rulemaking proceedings

listed in this Public Notice and

published pursuant to 47 CFR Section

1.429(e). The full text of these

documents are available for viewing and

copying in Room 239, 1919 M Street,

N.W., Washington, D.C. or may be

purchased from the Commission’s copy

contractor, ITS, Inc. (202) 857–3800.

Oppositions to these petitions must be

filed October 9, 1997. See Section

1.4(b)(1) of the Commission’s rule (47

CFR 1.4(b)(1)). Replies to an opposition

must be filed within 10 days after the

time for filing oppositions has expired.

Subject: Amendment of Part 90 of the

Commission’s Rules to Facilitate Future

Development of SMR Systems in the

800 MHz Frequency Band (PR Docket

No. 93–144, RMs–8117,8030,8029).

Implementation of Sections 3(n) and

322 of the Communications Act

Regulatory Treatment of Mobile

Services (GN Docket No. 93–252).

Implementation of Section 309(j) of

the Communications Act—Competitive

Bidding (PP Docket No. 93–253).

Number of Petitions Filed: 6.

Subject: Amendment of Part 90 of the

Commission’s Rules to Facilitate Future

Development of SMR Systems in the

800 MHz Frequency Band (PR Docket

No. 93–144, RMs–8117,8030,8029).

Implementation of Sections 3(n) and

322 of the Communications Act

Regulatory Treatment of Mobile

Services (GN Docket No. 93–252).

Implementation of Section 309(j) of

the Communications Act—Competitive

Bidding (PP Docket No. 93–253).

Number of Petitions Filed: 3.
Federal Register / Vol. 62, No. 185 / Wednesday, September 24, 1997 / Notices 49987

Subject: Amendment of parts 2 and 15

of the Commission’s Rules to Deregulate

the Equipment Authorization

Requirements for Digital Devices (ET

Docket No. 95–19).

Number of Petitions Filed: 2.

Subject: Amendment of the

Commission’s Rules to Relocate the

Digital Electronic Message Service from

the 18 GHz band to the 24 GHz band for

Fixed Service (ET Docket No. 97–99).

Number of Petitions Filed: 2.

Subject: Applicant for Authorizations

and Licenses of Certain Stations in

Various Services (WT Docket No. 97–

115).

Number of Petitions Filed: 5.

Federal Communications Commission.

Shirley Suggs,

Chief, Publications Branch.

[FR Doc. 97–25271 Filed 9–23–97; 8:45 am]

BILLING CODE 6712–01–M

FEDERAL RESERVE SYSTEM

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Board of

Governors of the Federal Reserve

System.

TIME AND DATE: 12:00 noon, Monday,

September 29, 1997.

PLACE: Marriner S. Eccles Federal

Reserve Board Building, C Street

entrance between 20th and 21st Streets,

N.W., Washington, D.C. 20551.

STATUS: Closed.

MATTERS TO BE CONSIDERED:

1. Personnel actions (appointments,

promotions, assignments,

reassignments, and salary actions)

involving individual Federal Reserve

System employees.

2. Any items carried forward from a

previously announced meeting.

CONTACT PERSON FOR MORE INFORMATION:

Mr. Joseph R. Coyne, Assistant to the

Board; (202) 452–3204. You may call

(202) 452–3207, beginning at

approximately 5 p.m. two business days

before this meeting, for a recorded

announcement of bank and bank

holding company applications

scheduled for the meeting.

Dated: September 19, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97–25407 Filed 9–19–97; 5:06 pm]

BILLING CODE 6210–01–P

FEDERAL TRADE COMMISSION

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Federal

Trade Commission.

TIME AND DATE: 12:00 p.m., Friday,

November 7, 1997.

PLACE: Federal Trade Commission

Building, Room 532, 6th Street and

Pennsylvania Avenue, N.W.,

Washington, D.C. 20580.

STATUS: Parts of this meeting will be

open to the public. The rest of the

meeting will be closed to the public.

MATTERS TO BE CONSIDERED: Portions

Open to Public: (1) Oral Argument in

Brake Guard Products, Inc., Docket 9277

Portions Closed to the Public: (2)

Executive Session to follow Oral

Argument in Brake Guard Products,

Inc., Docket 9277.

CONTACT PERSON FOR MORE INFORMATION:

Victoria Streitfeld, Office of Public

Affairs: (202) 326–2180. Recorded

Message: (202) 326–2711.

Donald S. Clark,

Secretary.

[FR Doc. 97–25521 Filed 9–22–97; 3:40 pm]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Office of the Secretary

Agency Information Collection

Activities: Submission for OMB

Review; Comment Request

The Department of Health and Human

Services, Office of the Secretary

publishes a list of information

collections it has submitted to the Office

of Management and Budget (OMB) for

clearance in compliance with the

Paperwork Reduction Act of 1995 (44

U.S.C. Chapter 35) and 5 CFR 1320.5.

The following are those information

collections recently submitted to OMB.

1. Study of the Implementation of the

Office of Minority Health’s Bilingual/

Bicultural Service Demonstration

Program—NEW—The Office of Minority

Health proposes to survey sites

participating in its Bilingual/Bicultural

demonstration grant program to obtain

general information on how the program

is being implemented. Type of

Respondents: demonstration sites;

Number of Respondents: 47; Burden

Estimate per Response to Verification

Survey: 4 hours; Total Burden for

Verification Survey: 188 hours; Burden

Estimate per Response to Telephone

Interview: 1 hour; Total Burden for

Telephone Interview: 47 hours. Total

Study Burden: 235 hours.

OMB Desk Officer: Allison Eydt.

Copies of the information collection

packages listed above can be obtained

by calling the OS Reports Clearance

Officer on (202) 690–6207. Written

comments and recommendations for the

proposed information collection should

be sent directly to the OMB desk officer

designated above at the following

address: Human Resources and Housing

Branch, Office of Management and

Budget, New Executive Office Building,

Room 10235, 725 17th Street N.W.,

Washington, D.C. 20503.

Comments may also be sent to

Cynthia Agens Bauer, OS Reports

Clearance Officer, Room 503H,

Humphrey Building, 200 Independence

Avenue S.W., Washington DC, 20201.

Written comments should be received

within 30 days of this notice.

Dated: September 12, 1997.

Dennis P. Williams,

Deputy Assistant Secretary, Budget.

[FR Doc. 97–25263 Filed 9–23–97; 8:45 am]

BILLING CODE 4150–04–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

This notice announces a forthcoming

meeting of a public advisory committee

of the Food and Drug Administration

(FDA). The meeting will be open to the

public.

Name of Committee: Ophthalmic

Devices Panel of the Medical Devices

Advisory Committee.

General Function of the Committee:

To provide advice and

recommendations to the agency on FDA

regulatory issues.

Date and Time: The meeting will be

held on October 20, 1997, 9 a.m. to 5

p.m., and October 21, 1997, 8:30 a.m. to

5 p.m.

Location: Holiday Inn, Walker and

Whetstone Rooms, Two Montgomery

Village Ave., Gaithersburg, MD.

Contact Person: Sara M. Thornton,

Center for Devices and Radiological

Health (HFZ–460), Food and Drug

Administration, 9200 Corporate Blvd.,

Rockville, MD 20850, 301–594–2053, or

FDA Advisory Committee Information

Line, 1–800–741–8138 (301–443–0572

in the Washington, DC area), code

12396, or from the Internet: http://